RECRUITING

Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer

Conditions

Cancer Genetic evaluation Germline genetic variant Genetic cancer Memorial Sloan Kettering Cancer Center 19-133

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to attempt to identify genetic mutations or other gene-based variations in adults and children who have cancer, or are likely to develop an inherited form of cancer, and potentially reduce their risk for cancer or treat the cancer earlier.

Official Title

Discovery and Characterization of Susceptibility Genes in Adults and Children With Suspected Hereditary Cancer Predisposition

Quick Facts

Study Start:2019-04-17

Study Completion:2029-04

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03922893

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Individuals who have undergone clinical and/or research genetic evaluation, found to have or not have a germline genetic variant (pathogenic, likely pathogenic, variant of uncertain/unknown significance, likely benign). * Individuals with or without a personal history of malignant or pre-malignant lesions who demonstrate: a) clinical findings suggestive of a genetic cancer susceptibility syndrome including very early age at onset, multiple primary malignancies, or other features; and/or b) family histories suggestive of a genetic cancer susceptibility syndrome, or c) other features suggesting inherited etiology of malignancy as determined by the PI. * Family members of the above participants. Both children (with parental consent as age appropriate) and adults are eligible to participation. * Individuals may or may not be enrolled MSK patients; probands may be referred to (or self-referred to) the study and may be enrolled at discretion of the PI and if able to provide informed consent. * Biospecimens derived from deceased family members may be used for research in this study if consent if provided by the executor of the estate of that individual.	* Patients will be excluded from this study if he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful informed consent.

Inclusion Criteria

Exclusion Criteria

* Individuals who have undergone clinical and/or research genetic evaluation, found to have or not have a germline genetic variant (pathogenic, likely pathogenic, variant of uncertain/unknown significance, likely benign).
* Individuals with or without a personal history of malignant or pre-malignant lesions who demonstrate: a) clinical findings suggestive of a genetic cancer susceptibility syndrome including very early age at onset, multiple primary malignancies, or other features; and/or b) family histories suggestive of a genetic cancer susceptibility syndrome, or c) other features suggesting inherited etiology of malignancy as determined by the PI.
* Family members of the above participants. Both children (with parental consent as age appropriate) and adults are eligible to participation.
* Individuals may or may not be enrolled MSK patients; probands may be referred to (or self-referred to) the study and may be enrolled at discretion of the PI and if able to provide informed consent.
* Biospecimens derived from deceased family members may be used for research in this study if consent if provided by the executor of the estate of that individual.

* Patients will be excluded from this study if he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful informed consent.

Contacts and Locations

Study Contact

Kenneth Offit, MD, MPH

CONTACT

646-888-4059

offitk@mskcc.org

Mark Robson, MD

CONTACT

646-888-5486

robsonm@mskcc.org

Principal Investigator

Kenneth Offit, MD, MPH

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (Consent only)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Consent only)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Consent only )

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Cancer Center @ Commack (Consent Only)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Consent only)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Consent only)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Kenneth Offit, MD, MPH, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-04-17

Study Completion Date2029-04

Study Record Updates

Study Start Date2019-04-17

Study Completion Date2029-04

Terms related to this study

Keywords Provided by Researchers

Genetic evaluation
Germline genetic variant
Genetic cancer
Memorial Sloan Kettering Cancer Center
19-133

Additional Relevant MeSH Terms

Cancer